119 related articles for article (PubMed ID: 8792010)
1. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.
Maki A; Mohammad R; Raza S; Saleh M; Govindaraju KD; Pettit GR; al-Katib A
Anticancer Drugs; 1996 May; 7(3):344-50. PubMed ID: 8792010
[TBL] [Abstract][Full Text] [Related]
2. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
Ali MA; Rosati R; Pettit GR; Kalemkerian GP
Anticancer Res; 1998; 18(2A):1021-6. PubMed ID: 9615758
[TBL] [Abstract][Full Text] [Related]
3. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
Beckwith M; Urba WJ; Longo DL
J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
[TBL] [Abstract][Full Text] [Related]
6. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
8. [The effects of RA538 and antisense c-myc on cervical cancer cell lines with high expression of bcl-2 gene].
Chen J; Lin C; Deng Y
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):279-82. PubMed ID: 11778549
[TBL] [Abstract][Full Text] [Related]
9. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Al-Katib AM
Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone).
Isaka K; Fujito A; Sagawa Y; Yudate T; Nishi H; Ito H; Takayama M
Oncol Rep; 2002; 9(6):1299-305. PubMed ID: 12375038
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
Klasa RJ
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Chang H; Blondal JA; Benchimol S; Minden MD; Messner HA
Leuk Lymphoma; 1995 Sep; 19(1-2):165-71. PubMed ID: 8574164
[TBL] [Abstract][Full Text] [Related]
15. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines.
Reed JC; Kitada S; Takayama S; Miyashita T
Ann Oncol; 1994; 5 Suppl 1():61-5. PubMed ID: 8172820
[TBL] [Abstract][Full Text] [Related]
16. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma.
Lee JT; Innes DJ; Williams ME
J Clin Invest; 1989 Nov; 84(5):1454-9. PubMed ID: 2509518
[TBL] [Abstract][Full Text] [Related]
17. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
18. Differential expression of apoptosis, Bcl-x and c-Myc in normal and malignant lymphoid tissues.
Hermann M; Scholman HJ; Marafioti T; Stein H; Schriever F
Eur J Haematol; 1997 Jul; 59(1):20-30. PubMed ID: 9260577
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma.
Song W; Liu MG; Zhang JB; Zhang JJ; Sun MM; Yu QK
Eur Rev Med Pharmacol Sci; 2016; 20(6):1093-7. PubMed ID: 27049262
[TBL] [Abstract][Full Text] [Related]
20. Effects of dolastatins on human B-lymphocytic leukemia cell lines.
Hu ZB; Gignac SM; Quentmeier H; Pettit GR; Drexler HG
Leuk Res; 1993 Apr; 17(4):333-9. PubMed ID: 8487581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
